Roche and Dyno Partner for $1B Gene Therapy Using AI-Enhanced AAV Capsids

Roche has formed a significant partnership with Dyno Therapeutics, potentially worth over $1 billion, to develop new gene therapies for neurological diseases. This collaboration involves an upfront payment of $50 million from Roche and leverages Dyno's AI-enhanced platform to create advanced adeno-associated virus (AAV) capsids aimed at overcoming challenges like existing immunity and payload limitations in current gene therapies[1][2]. Dyno specializes in discovering novel AAV capsids, while Roche is responsible for capsid validation, preclinical and clinical development, and commercialization[1]. This venture builds on their previous 2020 collaboration and positions Roche to strengthen its neurological pipeline, despite facing setbacks in other gene therapy areas[2].